Biopharmaceutical Company Imara Inc. Files Confidentially for IPO
13 Setembro 2019 - 9:26AM
Dow Jones News
By Colin Kellaher
Clinical-stage biopharmaceutical company Imara Inc. Friday said
it has confidentially filed a draft registration with the
Securities and Exchange Commission for a proposed initial public
offering.
The Boston company said the number of shares to be offered and
the expected price range haven't yet been determined.
Imara is working to develop treatments for a group of rare,
inherited genetic disorders of hemoglobin known as
hemoglobinopathies. The company's initial product candidate,
IMR-687, is in development for sickle cell disease and
beta-thalassemia.
Imara in March raised $63 million in a Series B funding round
led by Arix Bioscience PLC (ARIX.LN) and OrbiMed Advisors, with
participation from RA Capital, Rock Springs Capital, Alexandria
Venture Investments, Bay City Capital, Lundbeckfonden Ventures, New
Enterprise Associates and Pfizer Ventures.
The filing Imara submitted to the SEC isn't yet visible to the
public because the company has taken advantage of the commonly used
confidential-filing provision introduced in 2012 as part of the
Jumpstart Our Business Startups Act.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 13, 2019 08:11 ET (12:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Arix Bioscience (LSE:ARIX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Arix Bioscience (LSE:ARIX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
